FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

For research purposes only. Full disclaimer →

مكتبة البروتيدات

CagriSema

Cagrilintide + Semaglutide

Weight Loss & Metabolic

CagriSema is a fixed-ratio combination of semaglutide (a GLP-1 receptor agonist) and cagrilintide (a long-acting amylin analog), both developed by Novo Nordisk. This dual-mechanism injectable targets two complementary appetite and metabolic pathways simultaneously. It is in Phase 3 clinical trials and represents Novo Nordisk's next-generation obesity treatment strategy following semaglutide monotherapy.

mechanism of action

Fixed-dose combination of cagrilintide (amylin analog) and semaglutide (GLP-1 agonist). Targets three distinct appetite and metabolic pathways simultaneously.

Research Protocols

للاستخدام البحثي فقط. ليس مشورة طبية.

Research protocols use the combination in a single weekly injection. Phase 3 doses range from cagrilintide 2.4mg + semaglutide 2.4mg weekly.

Research Notes

Clinical Research Status

CagriSema is in Phase 3 trials (REDEFINE program) for obesity and type 2 diabetes, with regulatory submissions anticipated based on trial readouts. Phase 2 data demonstrated approximately 15.6% body weight loss at 32 weeks, numerically superior to semaglutide 2.4mg alone. The REDEFINE 1 Phase 3 trial reported up to 22.7% weight loss at 68 weeks, positioning it competitively against tirzepatide.

Key Published Findings

The dual amylin/GLP-1 approach produces additive weight loss beyond either mechanism alone, supporting the hypothesis that multi-receptor targeting enhances metabolic outcomes. Glycemic improvements were also observed, with potential for combined diabetes and obesity indications. The mechanistic rationale rests on amylin's distinct CNS satiety signaling through the area postrema complementing GLP-1's hypothalamic and gut-mediated effects.

Safety Profile

The adverse event profile combines elements of both components, with gastrointestinal effects (nausea, vomiting, diarrhea) being most common during dose escalation. Tolerability appears manageable with appropriate titration schedules, though direct comparisons to monotherapy discontinuation rates are still being evaluated. Injection site reactions are consistent with other subcutaneous peptide therapies.

Comparison to Related Compounds

CagriSema competes directly with tirzepatide (Mounjaro/Zepbound), which uses a single molecule targeting GIP and GLP-1 receptors simultaneously. The two-molecule approach allows independent dose optimization of each component but requires a single co-formulated injection. Weight loss magnitude appears comparable to tirzepatide's 20-25% in similar trial durations, though head-to-head data is needed for definitive comparison.

Community Observations

The obesity research community views CagriSema as Novo Nordisk's answer to tirzepatide's superior weight loss over semaglutide monotherapy. Clinicians note that the combination format may offer flexibility for patients who plateau on GLP-1 monotherapy. The amylin component is reported to address residual hunger that some patients experience even at maximum GLP-1 doses.

Half Life

~7 days (combination)

Reconstitution

Pre-mixed formulation

Storage

Lyophilized

Refrigerate 2-8C.

Reconstituted

Refrigerate 2-8C. Use within 42 days.

US Legal Status

Research chemical (not FDA-approved)

Also Known As

Cagrilintide + Semaglutide

الأسئلة الشائعة

ما هو CagriSema؟

CagriSema is a fixed-ratio combination of semaglutide (a GLP-1 receptor agonist) and cagrilintide (a long-acting amylin analog), both developed by Novo Nordisk. This dual-mechanism injectable targets two complementary appetite and metabolic pathways simultaneously. It is in Phase 3 clinical trials and represents Novo Nordisk's next-generation obesity treatment strategy following semaglutide monotherapy.

كيف يعمل CagriSema؟

Fixed-dose combination of cagrilintide (amylin analog) and semaglutide (GLP-1 agonist). Targets three distinct appetite and metabolic pathways simultaneously.

ما هو الوضع التنظيمي لـ CagriSema في الولايات المتحدة؟

Research chemical (not FDA-approved)

ما هو عمر النصف لـ CagriSema؟

~7 days (combination)

ما الأسماء الأخرى لـ CagriSema؟

Cagrilintide + Semaglutide

Peptide Contacts provides research-based summaries for informational purposes only. We do not host, distribute, or endorse vendor documentation. All certificates of analysis, GMP certificates, and vendor communications must be requested and verified directly by the buyer. Nothing on this platform constitutes legal, medical, or professional advice. Users are solely responsible for verifying vendor credentials and ensuring compliance with all applicable local, state, and federal laws before purchasing any research chemicals. Use of this platform constitutes acceptance of full personal responsibility.

Read full disclaimer